The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InAmid intensifying scrutiny of the healthcare sector, nearly 5,000 independent pharmacies have filed a lawsuit against Prime Therapeutics alleging antitrust violations and price-fixing. The lawsuit claims a coordinated scheme in collaboration with Cigna's Express Scripts to impose unfair pricing structures that harm competition. According to reports, this legal action highlights the controversial practices of Pharmacy Benefit Managers (PBMs) in the U.S. market.
This lawsuit arrives as the PBM industry faces heightened regulatory pressure, with three major firms, including Express Scripts, controlling approximately 80% of the market per Federal Trade Commission (FTC) data. While Cigna's recent earnings showed strong growth in its Evernorth segment, mounting legal challenges could pressure profit margins. Per market data, peers like CVS Health and UnitedHealth are facing similar scrutiny regarding pricing transparency.
In the markets, CI stock stood at $281.98 (at close July 06, 2026), having traded between a day low of $275.8 and a high of $287.38. Investors are closely monitoring judicial developments that could impact the company's financial outlook, especially as the upcoming economic calendar lacks direct healthcare catalysts, leaving legal proceedings as the primary driver for the stock in the near term.